Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.

导出 LinkOut

翻译打印收藏纠错

作者： John,Belperio ^[1] ; Tuan,Nguyen ^[2] ; David A,Lombardi ^[2] ; Maxim,Bogus ^[3] ; Valentyn,Moskalenko ^[4] ; Dave,Singh ^[5] ; Brett,Haumann ^[6] ; David L,Bourdet ^[7] ; Elad,Kaufman ^[8] ; Nathan D,Pfeifer ^[2] ; Corbin G,Thompson ^[2] ; Jacky,Woo ^[2] ; Edmund J,Moran ^[2] ; Rajeev,Saggar ^[2]

作者单位： Ronald Reagan UCLA Medical Center, Los Angeles, California, USA. ^[1] Theravance Biopharma Inc, South San Francisco, California, USA. ^[2] Arensia Exploratory Medicine SRL, Chișinău, Moldova (the Republic of). ^[3] Timofei Mosneaga Republican Hospital, Chișinău, Moldova (the Republic of). ^[4] Arensia Exploratory Medicine, LLC, Kyiv City Clinical Hospital #12, Oleksandrivska Kyiv City Clinical Hospital, Kyiv, Ukraine. ^[5] Brovary Multidisciplinary Clinical Hospital, Brovary, Ukraine. ^[6] Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK. ^[7] Theravance Biopharma UK Limited, London, UK. ^[8] Theravance Biopharma Inc, South San Francisco, California, USA emoran@theravance.com. ^[9]

关键词 COVID-19 Nebuliser therapy

主题词人类(Humans);呼吸功能不全(Respiratory Insufficiency);氧(Oxygen)

DOI 10.1136/bmjresp-2023-001627

PMID 37460276

发布时间 2023-07-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

BMJ open respiratory research

2023年10卷1期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.

BMJ open respiratory research

相似文献

BMJ open respiratory research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial.

BMJ open respiratory research

相似文献

BMJ open respiratory research

相关期刊

检索历史清除